Ninepoint Partners’s AstraZeneca AZN Stock Holding History

Ninepoint Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$4.23K	Buy	+23	New	+$4.03K	﹤0.01%	146

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ninepoint Partners's AZN Position: Q4 2025 in Review

Ninepoint Partners opened a new position in AstraZeneca (AZN) in Q4 2025: 23 shares worth $4.23K. The stake represents ﹤0.01% of the portfolio and ranks #146 among its holdings.

1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Ninepoint Partners held 23 shares of AstraZeneca worth $4.23K as of Q4 2025.
AstraZeneca was a new Ninepoint Partners position in Q4 2025.
AstraZeneca made up ﹤0.01% of Ninepoint Partners's portfolio in Q4 2025, its #146 holding.
1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Ninepoint Partners's 13F filing for Q4 2025, filed 17 Feb 2026.